Meihua Biotech (600873): Plans to implement interim dividends and share repurchase cancellation
Meihua Biology (600873): Performance is in line with expectations, focusing on synthetic biology
Meihua Biotech (600873): Q2 deducts net profit month-on-month growth, and the amino acid boom improves
Meihua Biotech (600873): Q2 results are in line with expectations, amino acid price increases strengthen profitability
Meihua Biotech (600873): H1 net profit increased year-on-year, and the amino acid boom increased
Meihua Biology (600873): Amino acid industry leader moving towards synthetic biology platform-based enterprise
Meihua Biotech (600873): The leading multi-category layout in the global amino acid industry continues to gain strength
104 shares received a buying rating from brokerage firms, and Meihua Biotech's target increase of 54.74%
Meihua Biotech (600873): Performance is in line with market expectations, and the price difference between alcohol and lysine continues to rise
Guolian Securities released a research report on April 9 stating that Meihua Biotech (600873.SH) was given a purchase rating. The main reasons for the rating include: 1) the quantity and price of feed amino acids have risen sharply, and the performance is
Meihua Biotech (600873): Leading amino acid enterprise platform achieves development
Meihua Biotech (600873): Price decline is dragging down revenue and waiting for the amino acid boom to recover
Meihua Biotech (600873): Q1 net profit declined slightly year-on-year, and the amino acid boom picked up
Meihua Biotech (600873): Achieved a high annual performance in the fourth quarter and is committed to becoming a leading synthetic biology company
Meihua Biotech (600873): Continued high dividends, high performance growth in the fourth quarter
Meihua Biotech (600873): Amino acid production and sales continue to grow, scale advantage consolidates Zhuang Tingzhou
Meihua Biotech (600873): The performance is in line with expectations, and the high percentage of dividends highlights the company's long-term value
Meihua Biotech (600873) Comment: Employee Stock Ownership Plan Released Demonstrates Confidence in the Company's Development
Meihua Biotech (600873): Continuing to buy back and increase holdings Meihua executives are firmly optimistic about the company's development
Meihua Biotech (600873): A new round of employee stock ownership plans strengthens long-term corporate incentives
No Data
No Data